Guanylate cyclase C (GUCY2C) is a tumor suppressing receptor silenced by loss of expression of its luminocrine hormones guanylin and uroguanylin early in colorectal carcinogenesis. This observation suggests oral replacement with a GUCY2C agonist may be an effective targeted chemoprevention agent. Linaclotide is an FDA approved oral GUCY2C agonist formulated for gastric release, inducing fluid secretion into the small bowel to treat chronic idiopathic constipation. The ability of oral linaclotide to induce a pharmacodynamic response in epithelial cells of the colorectum in humans remains undefined. Here, we demonstrate that administration of 0.87 milligrams of oral linaclotide daily for 7 days to healthy volunteers, after oral colon preparation with polyethylene glycol solution (MoviPrep), activates GUCY2C, resulting in accumulation of its product cyclic (c)GMP in epithelial cells of the cecum, transverse colon, and distal rectum. GUCY2C activation by oral linaclotide was associated with homeostatic signaling, including phosphorylation of vasodilator-stimulated phosphoprotein and inhibition of proliferation quantified by reduced Ki67-positive epithelial cells. In the absence of the complete oral colonoscopy preparation, linaclotide did not alter cGMP production in epithelial cells of the colorectum, demonstrating that there was an effect related to the laxative preparation. These data show that the current FDA-approved formulation of oral linaclotide developed for small bowel delivery to treat chronic idiopathic constipation is inadequate for reliably regulating GUCY2C in the colorectum to prevent tumorigenesis. The study results highlight the importance of developing a novel GUCY2C agonist formulated for release and activity targeted to the large intestine for colorectal cancer prevention.
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This work was sponsored by the National Cancer Institute, Division of Cancer Prevention S. residents will be diagnosed with this disease. Despite advances in early detection and treatment, the mortality rate for colorectal cancer remains nearly 50%. Although screening and surveillance continue to be the cornerstone of colorectal cancer prevention, chemoprevention has emerged as a complementary approach among higher risk participants. To date, aspirin (ASA) and other nonsteroidal anti-inflammatory drugs (NSAIDs) represent the most thoroughly investigated class of colorectal cancer chemoprevention agents. However, given the established risk/benefit profile of these agents, the widespread use of ASA or other NSAIDs strictly for colorectal cancer chemoprevention seems unlikely in the average-risk population.
Guanylate cyclase C (GUCY2C) is the intestinal epithelial cell receptor (2) 
Primary Endpoints
The primary endpoint of the study was to identify a dose of linaclotide that produced a 60% Cyclic GMP levels were normalized to the protein content from individual samples.
Phosphorylation of VASP
VASP phosphorylation from sites in the colon was quantified by immunoblot analyses of biopsy specimens from normal mucosa employing commercially available antibodies (Phospho-VASP (Ser239) Antibody, Cat: # 3114, Cell Signaling, Danvers, MA). At least two biopsy specimens from each anatomical location were evaluated by two independent immunoblot analyses with quantification by densitometry and normalization to villin (VIL1), and the resulting 4 individual results averaged for comparisons.
Ki67
The impact of linaclotide on cell proliferation index (number of proliferating cells) was quantified employing Ki67 immunohistochemistry (Monoclonal Mouse Anti-Human Ki-67
Antigen, Clone MIB-1, Cat. #M7240, DAKO, Carpinteria, CA). At least two biopsy specimens from each anatomical location were evaluated by enumerating Ki67-positive cells in 15 crypts, and the resulting individual crypt cell counts pooled for comparisons.
Safety
To confirm the safety and tolerability of linaclotide and placebo, all participants were monitored for toxicity from the time of their first dose of linaclotide/placebo. CTCAE version 4.0 was used to summarize adverse events.
Statistical Analyses
Frequency tables and percentages summarized baseline and clinical characteristics, treatment data, and adverse event data, overall and by stage for each treatment arm. Descriptive statistics, including mean, standard deviation, median, range, and frequencies (percentages), were used to summarize these data. Fisher's Exact and Wilcoxon Rank-Sum tests were used to test for associations between treatment arms and categorical and continuous data, respectively. All statistical tests were 2-sided and performed using SAS version 9.4 (SAS Institute, Inc.). Associations between treatment arms and secondary endpoints, including Ki67
and VASP phosphorylation, were performed using student's t test, using p<0.05 as the threshold for significance.
Results

Subject Characteristics
For this study, 46 subjects were screened, with 22 determined to be screen failures (Fig. 1) . The 24 subjects enrolled had a mean age of 47.7 + 6.3 years, 79.2% were male, 45.8% were white, and 54.2% were black (Table 1 ). Physical exams and laboratory studies revealed no clinically remarkable findings for this cohort of normal healthy volunteers (Supplementary Table 1 ).
Subjects randomized to linaclotide and placebo groups had similar characteristics except for a slightly higher BMI in the linaclotide group (Supplementary Table 1 ). Six subjects (5 placebo, 1 linaclotide) had polyps >2 mm detected and removed at the pre-intervention colonoscopy (Supplementary Table 2 ): 3 were tubular adenomas (all received placebo) and 3 were hyperplastic polyps (1 received linaclotide, 2 received placebo).
GUCY2C Activation
Stage I
In Stage I, 0.87 mg of oral linaclotide for 7 days produced pharmacological responses, increasing cGMP levels in epithelial cells of the cecum (Supplementary Table 3 ), transverse colon (Supplementary Table 4 ) and rectum (Supplementary Table 5 ) in two of three subjects receiving the active agent. Pharmacological responses reflected PD responses in those two subjects in all anatomical sites, including the rectum (Supplementary Tables 3-5 , Fig. 2 ). PD responses in those two subjects were associated with clinical responses of increases in stool frequency and decreases in stool consistency on most days of dosing. In contrast, the subject who received linaclotide but did not have cGMP PD responses also did not experience a change in bowel 13 movements. Cyclic GMP responses were associated with increases in the phosphorylation of the downstream effector VASP in those subjects, but not in subjects who received placebo or in the one subject that received linaclotide but did not have a PD response (Fig. 3) . Similarly, cGMP PD responses to linaclotide were associated with reduced crypt proliferation in all anatomical segments, quantified by Ki67 immunohistochemistry (Fig. 4) .
Stage II
PD responses in 2 of 3 actively treated subjects qualified as success, advancing the trial to Stage II ( Fig. 1) . In this stage of the study, all procedures were identical to Stage I, including an oral bowel preparation, except pre-and post-intervention rectal biopsies were obtained by sigmoidoscopy (assessed only for cGMP levels). As in stage I, 0.87 mg of oral linaclotide for 7 days produced a PD response in 2 subjects, increasing cGMP levels in epithelial cells in the rectum (Fig. 5A ) in two of three subjects receiving the active agent. As before, PD responses in those two subjects were associated with an increase in stool frequency and a decrease in stool consistency while the subject who received linaclotide but did not have cGMP PD responses also did not experience a change in bowel movements. Again, PD responses in 2 of 3 actively treated subjects qualified as success, advancing the trial to Stage III (Fig. 1) .
Stage III
In this stage of the study, all procedures were identical to stage 2 except subjects received tap water enemas, rather than oral MoviPrep, prior to collection of pre-and post-intervention rectal biopsies by sigmoidoscopy and assessment of cGMP levels (Fig. 1) . Unlike Stages I and II, 0.87 mg of oral linaclotide for 7 days did not produce a PD response in subjects receiving active 14 treatment (Fig. 5B) . Moreover, no subject in this group experienced a change in bowel movements with linaclotide administration. As these results were unanticipated, we searched the research literature identifying one report suggesting that tap water enemas can disrupt the overlying epithelium sampled by endoscopic biopsy. In that context, changes in cGMP produced by linaclotide only occurred in epithelial cells, since they expressed the GUCY2C receptor. In contrast to tap water, PEG enemas preserve epithelia by endoscopic biopsy. (21) We amended the protocol so Stage III included a cohort that received a PEG enema instead of the tap water enema. However, 0.87 mg of oral linaclotide for 7 days did not produce a PD response in subjects even following the PEG enema with MoviPrep (Fig. 5C ). The study was terminated because linaclotide failed to produce a PD response in at least two subjects in this cohort.
Safety
The dose of linaclotide employed here, 0.87 mg, was well tolerated and all subjects completed their full 7 days of dosing without discontinuation or dose reduction. Adverse events were all grade 1 by CTCAE criteria, and all subjects, linaclotide and placebo arms, experienced at least 1 adverse event during the study. Adverse events were similar in both intervention cohorts, except for an increase in bowel frequency and a decrease in consistency, an expected effect of exposure to linaclotide (Supplementary Table 6 ). Post-intervention endoscopy findings were similar in the linaclotide and placebo groups (Supplementary Table 7) .
Discussion
In health, GUCY2C plays a key regulatory role in proliferative and metabolic processes that oppose tumorigenesis. However, the near universal over-expression of GUCY2C in human These observations suggest concrete steps for advancing GUCY2C as a target for colorectal cancer chemoprevention by oral hormone replacement therapy. For example, future studies 
